Landmark clinical observations and immunopathogenesis pathways linked to HIV and Cryptococcus fatal central nervous system co-infection

Samuel Okurut¹,² | David R. Boulware³ | Joseph Olobo⁴ | David B. Meya¹,³,⁵

¹Research Department, Infectious Diseases Institute, Makerere University, Kampala, Uganda
²Department of Microbiology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda
³Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota
⁴Department of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda
⁵Department of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda

Correspondence
Samuel Okurut, Research Department, Infectious Disease Institute, Makerere University, Kampala, Uganda.
Email: okuruts@gmail.com

Funding information
This work was supported, in part, by the funding from National Institute of Health Fogarty International Center training grant (2D43TW009771-06 [YCM]) and GlaxoSmithKline Trust in Science Africa research capacity building grant (COL100044928- [S.O]).

Summary
Cryptococcal meningitis remains one of the leading causes of death among HIV-infected adults in the fourth decade of HIV era in sub-Saharan Africa, contributing to 10%-20% of global HIV-related deaths. Despite widespread use and early induction of ART among HIV-infected adults, incidence of cryptococcosis remains significant in those with advanced HIV disease. Cryptococcus species that causes fatal infection follows systemic spread from initial environmental acquired infection in lungs to antigenemia and fungaemia in circulation prior to establishment of often fatal disease, cryptococcal meningitis in the CNS. Cryptococcus person-to-person transmission is uncommon, and deaths related to blood infection without CNS involvement are rare. Keen to the persistent high mortality associated with HIV-cryptococcal meningitis, seizures are common among a third of the patients, altered mental status is frequent, anaemia is prevalent with ensuing brain hypoxia and at autopsy, brain fibrosis and infarction are evident. In addition, fungal burden is 3-to-4-fold higher in those with seizures. And high immune activation together with exacerbated inflammation and elevated PD-1/PD-L1 immune checkpoint expression is immunomodulated phenotypes elevated in CSF relative to blood. Lastly, though multiple Cryptococcus species cause disease in this setting, observations are mostly generalised to cryptococcal infection/meningitis or regional dominant species (C. neoformans or gattii complex) that may limit our understanding of interspecies differences in infection, progression, treatment or recovery outcome. Together, these factors and underlying mechanisms are hypotheses generating for research to find targets to prevent infection or adequate therapy to prevent persistent high mortality with current optimal therapy.

KEYWORDS
B-cell immune regulation, brain fibrosis, central nervous system evasion, HIV-associated cryptococcal meningitis co-infection, Human Cryptococcus infection, immune activation, pathogenesis, PD-1/PD-L1 immune regulation, treatment outcome
1 | INTRODUCTION

The central nervous system (CNS) (brain, cerebrospinal fluid (CSF) and spinal cord) provides a formidable niche for disseminated fatal cryptococcal meningitis.1–2 Cryptococcal meningitis is an acute fungal disease caused by an encapsulated yeast of the genus Cryptococcus.3 Cryptococcus emerged from the environment to cause disease in man and the species that cause fatal infection have high preference to infect the CNS to cause meningoencephalitis in individuals with ensuing immunosuppression.2,4–6 Several species of Cryptoccus exist with Cryptococcus neoformans complex and Cryptococcus gattii complex leading infection in those with an underlying immunosuppression.3,5,7–13 The C neoformans species complex comprise of C neoformans sensu stricto that causes 60%–90% of HIV-associated cryptococcal meningitis together with C deneiformans and hybrids between both species.8–11,14,15 Prior to individual species characterisation, C gattii complex was known to cause disease mostly among individuals without HIV infection.6,8 But to date increasing reports of different species of C gattii complex are being documented to cause disease among HIV immunocompromised patients globally.8 The C gattii species complex includes C gattii sensu stricto (AFLP4/VGI), C deuterogattii (AFLP6/VGII), C bacillisporus (AFLP5/VGII), C tetragattii (AFLP7/VGIV) and C decagattii (AFLP10/VGIII and VGIV).7,10,16–18 Thus, the limitations of existing diagnostic tests in common clinical use that are unable to identify species-related infection may limit our understanding of information related to species-specific infection, pathogenesis and disease outcome. The species-related information may be relevant in designing treatment strategies amidst high residual cryptococcal meningitis-related deaths with optimal use of antifungal drugs to treat those co-infected with HIV.

Among HIV-infected adults (>18 years of age), cryptococcal meningitis is diagnosed in CSF 7–28 days from onset of symptoms.19–24 However, early symptoms including fever and headache may complicate early diagnosis and delay antifungal treatment in regions with other endemic pathogens that present with similar symptoms.20,21,25,26 Cryptococcosis results in 20%–40% HIV-related deaths worldwide.23,27 Among HIV-infected adults, CD4 T-cell count < 100 cell/μL is one of the risk factors for cryptococcosis.20,23,28 However, despite attempts to restore and maintain immune response with early antiretroviral therapy (ART) among HIV-infected individuals with higher CD4 T cells, some persons still present with high incidence of HIV-associated cryptococcosis.23,29–32 Surprisingly, among regions with a high incidence of HIV-associated cryptococcosis, one would relate incidence of infection with frequent yeast exposure from the environment. But rare infection among healthy individuals in this regions alters this speculation.23

Hence, the challenges in the pathogenesis of human Cryptococcus infection have led to the incidence of cryptococcosis remaining significant over the last three to four decades of the HIV/AIDS epidemic especially in sub-Saharan Africa.21,23,30,34,35 Indeed, persistent high mortality from HIV-associated cryptococcosis occurs with the use of optimal antifungal drugs and HAART for the treatment of those co-infected.20–23 It remains unclear what constitutes a translational mechanism to attenuate this high mortality among those with HIV-associated cryptococcosis. Of note, in large cryptococcosis cohorts, factors associated with treatment failure have been inconsistently reported.20–24,36,37 Hence, this review aims to point the field to the cryptococcosis immunopathogenesis factors and pathways to be targeted in further investigations to prevent infection or to alter persistent poor treatment outcome.

2 | PATHOGENESIS OF HUMAN CRYPTOCOCCOSIS INFECTION

The initial Cryptococcus infection is postulated to occur in the lungs where alveolar macrophages, (the primary cells to encounter Cryptococcus) together with activated Th1 and Th17 cells form the cornerstone of protection.2,27 In theory, recruited activated immunocytes surround infected primary macrophages to form a granuloma.27,38 During this process, the primary infection is contained through phagocytosis leading to complete resolution of infection or through evasion of phagocytosis leading to establishment of latency. The evidence for cryptococcosis resolution without disease onset (aborted infection) and/or latency is based on the presence of Cryptococcus-positive binding antibodies in children that demonstrate early exposure to the fatal yeast.39 Among children and adults who develop active cryptococcosis, progression follows an onset of HIV and other immunosuppressive disease condition including HIV advanced disease.40,43,40 Hence, latent Cryptococcus infection may persist for a lifetime among Cryptococcus exposed individuals without an underlying immunosuppression trigger.23,41,42

It is proven by molecular diagnostics (eg MLST on cultures) that Cryptococcus tetragattii (known to only occur in Africa/India) can be dormant or latent for 20–30 years after exposure, for example in immigrants who develop cryptococcal meningitis with strains from country of origin after acquiring HIV in the country of residence.6,40,43 Similarly, C deuterogattii infection (Vancouver Island outbreak-causing Cryptococcus species) is observed to cause disease among tourists who developed disease years after a touristic visit to the affected area in North America with several European case reports of people who had underlying diseases, like in systemic lupus erythematosus.6,8,43,44 Thus, without an onset of HIV immune suppression mostly in sub-Saharan Africa and Asia Pacific regions and without onset of malignancies and cancer treatment, solid organ transplant conditioning in the developed world, and prolonged hospitalisation, latent Cryptococcus infection may potentially not progress to fatal cryptococcal meningitis.45–48 Other factors associated with onset of active Cryptococcus infection include the following: loss of quality multifunctional CD4 T cells among HIV-infected individuals,49,50 loss of IgM + memory B cells (innate-like IgM producing memory B cells) among HIV-infected adults,51 use of B cell-depleting antibody therapies (rituximab and infliximab) among cancer patients,57,52,53 defects in the FCγ receptor polymorphism54–56 and fungal evasion of phagocytosis (immune escape).38,57,58
Conversely, whether fatal systemic cryptococcosis is due to new infection or reactivated latent infection is not clearly understood.\textsuperscript{24,59} However, Cryptococcus genotyping studies from clinical isolates of emigrants with Cryptococcus strains from endemic regions support both the latent and new environmental acquired Cryptococcus infection causality theories.\textsuperscript{5,60} That, individuals who travel and developed cryptococcosis infection with strains endemic to their region support the latent infection theory. Clearly, from European multilocus sequence typing (MLST)—studies, as above mentioned with immigrants from, for example Africa who developed C tetragattii infection ~26 years after immigrated from Zambia to Sweden where the patient acquired HIV followed by cryptococcal meningitis, the isolated strains were identical to the C tetragattii lineage from Southern Africa.\textsuperscript{40} And that, similar MLST studies in Africa, Americas and Asia among adult travellers and immigrants who develop cryptococcosis infection with strains endemic to regions they travelled or settled support the new infection theory.\textsuperscript{6,8,9} Moreover, person-to-person transmission of Cryptococcus to cause infection is rare.\textsuperscript{6,8,9,11,43} Thus, the limited cryptococcosis person-to-person transmission limits genetic recombination between Cryptococcus species and maintains environmental acquired Cryptococcus strain clonality that is easily traced to the origin of acquisition. And the lack of person-to-person transmission of cryptococcosis limits public attention towards this debilitating disease among HIV immune compromised patients. Thus, Cryptococcus host exposure dynamics from environment to cause infection together with host immunogenetic factors and mechanisms may influence onset of fatal cryptococcosis.\textsuperscript{2,10,12,13,16-18,61} And deeper investigation may leverage the mechanisms of infection to alter onset of fatal cryptococcal meningitis or prevent deaths among those undergoing treatment.

3 | CRYPTOCOCCUS CENTRAL NERVOUS SYSTEM INFECTION

Recent findings indicate several Cryptococcus transmission mechanisms are used by the yeast to infect the CNS. The trojan horse model, where Cryptococcus-infected macrophages, traverse the blood-brain barrier (BBB) to infect the central nervous system.\textsuperscript{62} This trojan horse mechanism is also observed to facilitate HIV transmission across the BBB in response to intrathecal CCL2 chemokine stimulation.\textsuperscript{63} And, restriction of adhesion molecules (JAM-A and ALCAM and chemokine receptors (CCR2 and CCR5) with inhibitory antibodies restricted monocytes trafficking to the CSF lowered CSF HIV viraemia.\textsuperscript{63} Transcytosis is another mechanism, where Cryptococcus, with the help of cellular binding motifs and adhesion molecules, manoeuvres through interstitial cellular spaces of the BBB and the brain parenchyma to infect the CNS. Dendritic cells are also associated with the transcytosis mechanism of compartmentalised pathogen transmission. Lastly, paracytosis is another mechanism where Cryptococcus with the help of secreted proteases digest its way through the cells lining the BBB to gain access of the CNS.\textsuperscript{62,64} Thus, interruption of the pathways that aid Cryptococcus access to the CNS where it establishes fatal disease could alter clinical outcomes.\textsuperscript{23,45,65}

The evidence that Cryptococcus is predominant in the CSF compartment of individuals with cryptococcal meningitis (Figure 1),\textsuperscript{24,66} suggests that the fungus influences host immunological and treatment outcomes via its effects on the central nervous system (brain, spinal cord, and CSF). Thus, the predominance of the facultative extracellular Cryptococcus in the closed CSF interacting with immunocytes may be a translational target to model innate and adaptive immune factors and mechanisms of infection and treatment outcome. But the perturbing question is the elusive role and the lack of clinical relevance of the CSF immunocytes in influencing infection and treatment outcome. Evidence from a Ugandan cohort suggests that some individuals with asymptomatic cryptococcosis present with measurable cryptococcal antigen in blood but not in CSF.\textsuperscript{23,29} And another observation suggests that Cryptococcus is unable to proliferate in CSF supernatant from healthy individuals without apparent immunosuppression.\textsuperscript{38} The above two pieces of observations contradict our understanding of the role of CSF in merely supporting establishment of fatal cryptococcosis.

4 | PD-1 EXPRESSION ON THE CEREBROSPINAL FLUID IMMUNOCYTES

The immunocytes in the CSF comprise of activated (HLA-DR/CD38) mature T cells (CD4 and CD8 T cells), monocytes (CD14/CD16; Classical monocytes, Intermediate monocytes and alternative monocytes) and

![FIGURE 1](Image1.png)

Flow cytometry representation of the cellular lineage of fresh cerebrospinal fluid from a subject with HIV-associated cryptococcal meningitis. A, magnified encapsulated cryptococcal cells, India ink staining and viewed under a light microscope. B, CSF cell pellet stained with CD45 fluorescent labelled antibodies and analysed using a flow cytometer. Here, CD45 is a pan white blood cell marker used to discriminate white blood cells from a mass of Cryptococcus cells.
natural killer (NK) cells (CD56/CD16; Bright, dim and negative NK cells). In addition, the B cells (CD19) in the CSF comprise of activated (CD21 low) and differentiated memory (CD27) and plasmablasts/plasma B cells. Surprisingly, from the above studies, activation and differentiation of the CSF cellular phenotype seem to be altered by programmed death-1 (PD-1; CD279) immune checkpoint receptor and programmed death-1 ligand (PD-L1; CD274) expression.

The PD-1 is a ubiquitous immune checkpoint transmembrane molecule that is expressed on lymphoid cells particularly on T follicular helper cells and on cells of the myeloid lineage with B cells, monocyte, macrophages and NK cells being effector cells. PD-1 expression is triggered following induced cellular activation. The PD-1 expression is maintained with persistent antigenaemia observed in chronic infections or in slowly resolving infection following treatment success. PD-1 interacts with its high-affinity ligand PD-L1 (CD274) expressed mostly on antigen presenting cells (monocytes, macrophages and dendritic cells).

PD-1 expression on CSF B cells, T cells and monocytes is much higher in the CSF compartment compared to the peripheral circulation during cryptococcosis. Additionally, on monocytes, PD-L1 expression in human cryptococcosis is equally higher in CSF compared to its expression in peripheral circulation. Moreover, the majority of CSF immune cells during human cryptococcosis are highly activated compared to those in circulation. Thus, whether the high PD-1 expression is due to cryptococcal evasion of CNS infection or a host mechanism to downregulate Cryptococcus induced CSF/CNS activation remains unclear.

The PD-1/PD-L1 interaction results in negative feedback signalling that downregulates activated responses. On effector cells, persistent PD-1/PD-L1 interaction results in immune unresponsiveness with consequent immune exhaustion. Therefore, host PD-1 induction as a mechanism to circumvent induced pathogen activation may work in synergy against the host to facilitate immune escape by the pathogen to the detriment of the host. For example, shutting down immune activation could facilitate unchecked pathogen replication to the detriment of the host. In addition, exhaustion of immune responses may induce host-pathogen immune induced tolerance hence accumulation of pathogen host induced damage responses that may lead to host clinical deterioration. In summary, irrespective of the effector cell, the PD-1/PD-L1 interaction inhibits cellular activation, proliferation, antibody production and cytokine expression. Conversely, it is possible that alteration of PD-1/PD-L1 interaction by either PD-1/PD-L1 blockers restores/reconstitutes the exhausted/inhibited response. Thus, further interrogation of the PD-1/PD-L1 pathway in human cryptococcal infection may alter the outcomes of this debilitating disease.

5 | PD-1 EXPRESSION ON LUNG IMMUNOCYTES

The mucosal lining of the lung provides easy access by the scavenging cells, including the macrophages and dendritic cells to gain access to the inhaled pathogens to influence onset of infection. In mouse models of cryptococcosis, persistent lung infection sustains PD-1 expression on dendritic cells and on macrophages. Moreover, sustained PD-1 expression on the macrophages on cryptococcosis brain mouse models promotes fungal growth through upregulated proliferation of Cryptococcus-infected macrophages, facilitating fungal dissemination. The PD-1 upregulation further increases activation of microglial cells and promotes Th2 cellular-activated responses while downregulating Th1-activated responses. Of note, application of anti-PD-1/PD-L1 antagonists (PD-1 blocking antibodies) altered PD-1-modulated responses by promoting fungal clearance, upregulating ICOS and XOXO40 on Th1, Th2, Th17 and regulatory T cells while downregulating IL-5 and IL-10 immune regulatory cytokines in the model of cryptococcosis. In addition, similar responses were observed with IL-10 blockade in experimental cryptococcal infection.

The IL-10 modulates immune response in a similar manner as PD-1 by modulating immune activation, cellular proliferation and cytokine expression in addition to modulation of cellular differentiation. Moreover, markers that induce PD-1 expression on B cells are found to induce IL-10 expression in B cells through Toll-like receptor-9-mediated mechanism. The PD-1-binding antibodies (substitute for PD-L1) inhibit PD-1 interaction with its high-affinity ligand PD-L1, hence antagonising immune inhibitory activity of PD-L1 on effector cells and consequently restoring exhausted immune response as observed in the mouse model of lung cryptococcosis infection. The similar interpretation of PD-1-blocking antibodies could be translated to IL-10 inhibitory (blocking) antibodies in application.

6 | CENTRAL NERVOUS SYSTEM IMMUNE ACTIVATION AND INFLAMMATION

Immune activation and inflammation are a cornerstone of innate and adaptive immune system that influences the outcome of evoked immune response. Briefly, the host immune cells are equipped with pathogen recognition receptors that include Toll-like receptors (TLRs), complement receptors 1 and 2, C-type lectin, B-cell receptor (CD19) and T-cell receptor (CD3) et cetera that recognise and form complementary binding regions with conserved molecules (antigen-binding domains or epitopes and paratopes) often referred to as pathogen-associated molecular patterns (PAMPs). The PAMPs include surface or transmembrane molecules, intracellular antigens (proteins, mannoproteins, lipopolysaccharides, DNA and RNA).

Briefly, during an immune activation, antigen presenting cells (dendritic cells, macrophages, monocytes or B cells) survey and pick up fungal antigens, phagocyte antigens, and present processed antigens to B cells and T cells. In the process, cells of the innate immune system link their responses to cells of the adaptive immune system. Hence, the presented antigen cross links the T-cell or B-cell receptor to induce activation and stimulates polymerisation of the activation receptors (TLR, human leucocyte antigens (HLA-DR), (CD21) et cetera) and the activation of co-stimulatory receptors.
(CD80, CD86, CD28, et cetera) to form an activation synapse. Activation synapse guides activated signal to phosphorylate downstream of the activated cell to evoke an immune response. The produced immune response could be receptor activation (HLA-DR, PD-1, CD69 et cetera), cellular subset differentiation, antibody production (IgM (early infection), IgG and IgG class-switched isotypes (IgG 1, 2, 3 or 4; later/reinfection), IgA (mucosal surfaces), cytokine response (Th-1 cytokines; (IL-1β, IFN-γ, TNF-α, Th-2 cytokines; IL-4, IL-10, IL-5, IL-13, et cetera, Th-17 cytokines; IL-17, IL-23 et cetera), chemokine receptor or chemokine ligands (CXCR3 in response to CXCL9 and CXCL10 stimulation, CXCR5 in response to CXCL13 stimulation et cetera) or tolerance (anergy).

In this context, evasion of the CNS by Cryptococcus could overwhelm the system with aberrant immune activation and exuberant inflammation triggered by the fungal virulence antigens (melanin, polysaccharide capsule (GXM), production of enlarged titan fungal cells and other fungal virulence factors) induced by the fast replicating yeast during host evasion. The triggered cellular activation and pro-inflammatory cytokine response (IFN-γ, IL-1β, IL-6 and TNF-α et cetera) lead to an exuberant inflammation (cytokine storm) that manifests with raised intracranial pressure and meningoencephalitis.

The Cryptococcus infection of the CNS induces inflow (traffic jam) of intervening peripheral immune cells into the CNS, traversing the blood-brain barrier. Alternatively, Cryptococcus infection of the CNS could induce local CNS cellular activation and differentiation to produce intrathecal activated and inflammatory response. The difference in immune response in cryptococcal meningitis between blood and the CSF compartments shows the existence of marked activation and increased inflammation in CSF than in blood at onset of cryptococcal meningitis and at onset of cryptococcosis-IRIS. Moreover, aberrant immune activation and exuberant inflammation are associated with poor disease outcome in HIV-associated Cryptococcus neoformans meningitis infection in Uganda. Interestingly, the evoked cytokine response to Cryptococcus GXM can be manipulated in experimental setting. But, to our knowledge, whether evoked immune response is different with infecting Cryptococcus species is not very clear. Moreover, unlike C neoformans sensu lato that causes disseminated infection, C gattii sensu lato establishes localised infection.

The activation of PD-1 expression may be a factor to modulate aberrant immune activation and exuberant inflammation in Cryptococcus infection. The observation that PD-1 expression on plasmablasts/plasma cells is associated with HIV-associated cryptococcosis mortality adds to the possible relevance of B cells in modulating the course of HIV-associated cryptococcosis co-infection to influence treatment outcome. One study at cryptococcal meningitis diagnosis reported the PD-1 expression on circulating cell lineages at 2% of B cells (CD19 lymphocytes), 25% of T cells and 1% of monocytes. Another study at the same timing reported PD-1 expression on T cells at 60% of CD4 + T cells and 30% of CD8 + T cells with persistant high PD-1 expression on circulating T cells beyond 12 weeks of follow-up. In this case, it is not clear whether sustained PD-1 expression in cryptococcosis is due to persistent activation or another mechanism. But, whether PD-1 or its ligand expression is different with infecting Cryptococcus species is yet to be investigated.

In the HIV cohort, PD-1 expression persisted on T cells beyond 22-44 weeks of antiretroviral therapy. In compartments, PD-1 is highly expressed in localised tissue infections that may be indicator altered immune response or pathogen immune escape mechanisms. Thus, PD-1 though ubiquitous on immunocytes is predominantly expressed on T cells. The slow resolution of PD-1 expression on effector cells may indicate either persistent activation, slow resolution of the evaded response or infection Cryptococcus species specific.
HIV-infected host to arterial fibrosis. Moreover, induced PD-1-associated arterial stiffness persists for nearly a year. The PD-1 pathway like the Th-2 predominant immune response modulates the immune response resulting in shutting down of immune activation and inflammation leading to tolerance (immune non responsiveness) that may allow evading pathogen to thrive unchecked in the host.

Fibrosis may not be entirely bad, as may be used by the host as an attempt to limit the spread of infection. But fibrosis inducing factors may work in synergy with other Cryptococcus host susceptible factors like anaemia to impair oxygen supply to the vital organs like the heart and the brain (hypoxic hypoxia) and consequently impairing tissue survival. Hence, pathogens that survive in a hypoxic microenvironment like Cryptococcus, which evades and thrives in the macrophage, could take advantage of the induced hypoxia in the brain to survive while leading to fatal outcomes. Together, these host and pathogen factors that induce fibrosis could contribute to poor outcomes with cryptococcal meningitis.

In other studies, the PD-1/PD-L1 axis-induced tissue fibrosis is clearly demonstrated in the lungs and brains of HIV-infected patients. Together, brain tissue fibrosis (subarachnoid spaces and cerebellar) and arterial stiffness (anterior and posterior arteries) could limit the effectiveness of antifungal and antiretroviral drug penetration into the CNS. The limited drug entry to the CSF could, in turn, limit antigen clearance in those with arterial stiffness and may influence fungal recrudescence. Further induced brain tissue fibrosis could influence intracranial pressure. And exacerbated arterial stiffness could influence brain hypoxia and subsequent brain tissue infarction. It is plausible that targeted blood transfusion to increase blood oxygen carrying capacity especially to the brain, oxygen supplementation, use of anti-PD-1/PD-L1 antagonists (PD-1/PD-L1 blockers) and adjunct therapy to decrease immune activation in combination with standard antifungal treatment could improve treatment outcomes in cryptococcal meningitis. Inherently, PD-1 function is unaltered with immune status, in health and in induced host immune suppression as demonstrated in SIV macaque models of infection that makes the PD-1 pathway (Figure 2) amenable to a spectrum of disease conditions.

8 IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS)

The IRIS is a fatal condition associated with an exaggerated immune response to recall or persistent antigen following immune restoration with antiretroviral therapy. This is common among HIV-infected patients with opportunistic co-infections like cryptococcosis after they initiate ART. Thus, both Cryptococcus and or HIV infection may have profound effects on regulatory B-cell responses in the setting where C neoformans sensu lato and interspecies hybrids cause most disease. And how regulatory B-cell responses are reconstituted may influence immune activation and differentiation of both innate and adaptive immune response to impact on host recovery.

B cells are important regulators of the immune system. Their roles include production of pro-inflammatory cytokines, including IL-6, TNF-α and IFN-γ that may influence the extent of cryptococcosis-induced inflammation, immune activation and host damage responses. Interestingly, studies that have attempted to harness regulatory B-cell responses in chronic inflammatory disease conditions suggest that the quality of regulatory B cells rather than IL-10 production is important in determining disease outcomes. This implies that the mechanism and the quality of the induced regulatory B-cell function are more of cellular dependent and less reliant on the secreted soluble factors. Moreover, regulatory B-cell responses are observed to be downregulated in HIV infection. And, factors that influence HIV infection and disease progression including bystander cell activation and HIV Nef-induced bystander cell deaths may impair regulatory B-cell function. Thus, it is important that the role of regulatory B cell in cryptococcal meningitis and associated IRIS be defined as these cells may influence infection and disease outcome.

9 B-CELL IMMUNE REGULATION

Regulatory B cells constitute about 10% of circulating B cells characterised by CD24 expression, IL-10 production and production of anti-inflammatory cytokines. B cells are important regulators of the immune system. Their roles include production of pro-inflammatory cytokines, including IL-6, TNF-α and IFN-γ that may influence the extent of cryptococcosis-induced inflammation, immune activation and host damage responses. Interestingly, studies that have attempted to harness regulatory B-cell responses in chronic inflammatory disease conditions suggest that the quality of regulatory B cells rather than IL-10 production is important in determining disease outcomes. This implies that the mechanism and the quality of the induced regulatory B-cell function are more of cellular dependent and less reliant on the secreted soluble factors. Moreover, regulatory B-cell responses are observed to be downregulated in HIV infection. And, factors that influence HIV infection and disease progression including bystander cell activation and HIV Nef-induced bystander cell deaths may impair regulatory B-cell function. Thus, it is important that the role of regulatory B cell in cryptococcal meningitis and associated IRIS be defined as these cells may influence infection and disease outcome.

8 IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS)

The IRIS is a fatal condition associated with an exaggerated immune response to recall or persistent antigen following immune restoration with antiretroviral therapy. This is common among HIV-infected patients with opportunistic co-infections like cryptococcosis after they initiate ART. Thus, both Cryptococcus and or HIV infection may have profound effects on regulatory B-cell responses in the setting where C neoformans sensu lato and interspecies hybrids cause most disease. And how regulatory B-cell responses are reconstituted may influence immune activation and differentiation of both innate and adaptive immune response to impact on host recovery.

B cells are important regulators of the immune system. Their roles include production of pro-inflammatory cytokines, including IL-6, TNF-α and IFN-γ that may influence the extent of cryptococcosis-induced inflammation, immune activation and host damage responses. Interestingly, studies that have attempted to harness regulatory B-cell responses in chronic inflammatory disease conditions suggest that the quality of regulatory B cells rather than IL-10 production is important in determining disease outcomes. This implies that the mechanism and the quality of the induced regulatory B-cell function are more of cellular dependent and less reliant on the secreted soluble factors. Moreover, regulatory B-cell responses are observed to be downregulated in HIV infection. And, factors that influence HIV infection and disease progression including bystander cell activation and HIV Nef-induced bystander cell deaths may impair regulatory B-cell function. Thus, it is important that the role of regulatory B cell in cryptococcal meningitis and associated IRIS be defined as these cells may influence infection and disease outcome.

9 B-CELL IMMUNE REGULATION

Regulatory B cells constitute about 10% of circulating B cells characterised by CD24 expression, IL-10 production and production of anti-inflammatory cytokines. B cells are important regulators of the immune system. Their roles include production of pro-inflammatory cytokines, including IL-6, TNF-α and IFN-γ that may influence the extent of cryptococcosis-induced inflammation, immune activation and host damage responses. Interestingly, studies that have attempted to harness regulatory B-cell responses in chronic inflammatory disease conditions suggest that the quality of regulatory B cells rather than IL-10 production is important in determining disease outcomes. This implies that the mechanism and the quality of the induced regulatory B-cell function are more of cellular dependent and less reliant on the secreted soluble factors. Moreover, regulatory B-cell responses are observed to be downregulated in HIV infection. And, factors that influence HIV infection and disease progression including bystander cell activation and HIV Nef-induced bystander cell deaths may impair regulatory B-cell function. Thus, it is important that the role of regulatory B cell in cryptococcal meningitis and associated IRIS be defined as these cells may influence infection and disease outcome.
... transfer signals or through Toll-like receptor-9 signalling.72,83 The presence of microbial factors either through complement receptor activating cell-activating factor-F. (d). Inflammation induced by the presence of interferon family of cytokines; IFN-α/β, IL-1β, IL-6, IL-21 and or B cell-activating factor-F. (d). Inflammation induced by the presence of microbial factors either through complement receptor activating signals or through Toll-like receptor-9 signalling.82,83 The presence of an antigen that crosses the B-cell receptor induces downstream phosphorylation.82,125 Thus, quantification of the regulatory B-cell phenotypes in vitro is only a proxy for B-cell immune regulatory response rather than an ex vivo host equated response. This is true as in vitro regulatory B cell-induced IL-10 production requires several exogenous manipulations that may not measure up to in vivo host response.80 Thus, a range of factors and mechanisms may influence HIV and associated cryptococcal meningitis co-infection and treatment outcome. In health, potent vaccines and immune-based therapies work by allowing target infection to establish below a threshold for disease onset as the effector response is evoked to control infection.34 This implies that immune regulatory mechanisms are integral to a balanced immune response to infectious disease with less fatal effects (minimal host damage) prior to resolution of infection (with/without treatment).34 We postulate that B-cell immune modulatory mechanisms work in synergy with optimal treatment to regulate host damage responses to influence recovery.

The B-cell subset developmental pathway may play a major role in the control of cryptococcal infection. B cells together with other immunocytes synergise T-cell maturation. In an intact immune system, B cells are activated to produce antibodies. The B cells can activate naive T cells to aid in maturation of effector T cells. Moreover, during severe HIV immunosuppression, B cells and other immunocytes could become dysfunctional and unable to produce effector response that may influence immune reconstitution and host recovery.20–23,30,34 Moreover, the defects in T-cell activation and maturation are loosely linked to the onset of cryptococcal infection and associated disease outcomes.118,126,127

**FIGURE 3** Model of fatal cryptococcal infection irreversible with current optimal antifungal therapy among some HIV and cryptococcal meningitis co-infected patients. A, The subclinical lung infection may resolve without symptoms or may persist with latent infection. B, Blood infection indicated systemic spread. C, Central nervous system infection indicates onset of often fatal disease, cryptococcal meningitis. D, Clinical observations linked to poor survival outcome. E, Clinical observations associated with mostly CSF infection. F, Factors observed at autopsy.

**10 | ANTIBODY RESPONSE IN CRYPTOCOCCAL MENINGITIS**

In experiments to quantify Cryptococcus-specific GXM antibodies among subjects with confirmed cryptococcal meningitis co-infection by quantitative fungal culture, 45.7% of the subjects tested positive for Cryptococcus-specific GXM IgG antibody.128 Interestingly, after acid treatment of the specimens to dissociate antibody from antigen-bound immune complexes to release bound antibodies for measurement, 97.1% of subjects had detectable **GXM antibodies**. We postulate that B-cell immune modulatory mechanisms work in synergy with optimal treatment to regulate host damage responses to influence recovery.
to months following treatment) especially among index cases. Additionally, the antibody response may be produced in later stages of infection when the host may be already overwhelmed with the infection. This may render antibody response less beneficial to the debilitated host as most of the produced antibody response may end up being bound to immune complexes and to the polysaccharide capsule. Conversely, it could be interpreted that index cryptococcosis infection (without circulating protective antibodies) causes fatal disease in the susceptible host and not latent cryptococcosis (with circulating specific antibodies). This could be true since both the latent and new Cryptococcus infection cause cryptococcal meningitis.

11 | REGULATION OF B-CELL TRAFFICKING IN INFLAMMATION

The immune cells extravasate the peripheral and lymphatic circulation to survey for antigens in the tissues and extra cellular spaces. This movement of immune cells from circulation to the tissues is important and enables responsive immune cells to effect their activated responses. Following cellular activation, responsive immune cells induce chemokine receptor expression and production of adhesion molecules. The induced chemokine receptor and adhesion molecules bind ligand to facilitate cellular chemoattraction through an inducing signal gradient in the target site.

The chemokine receptor CXCR5 and its ligand CXCL13 recruit naïve activated B cells to the follicles of the germline centres, resulting in B-cell differentiation to plasma cells. The induction of CXCR5 and CCR7 receptors on B cells further activates responsive naïve B cells to migrate and localise in secondary and tertiary lymphoid tissues including the lymph node, Peyer’s patches, mucosal and gut-associates lymphoid tissues for further maturation. Seeding of activated immune cells to the inflammatory sites leads to formation of ectopic (tertiary) germinal centres that surround inflamed tissues. Other B-cell homing receptors to the inflammatory sites include expression of CXCR3 receptors in response to CCL9, CCL10 ligand induction. The response may be in addition to inducing interferon-inducible protein-10 (IP-10) and CCL11, which are associated with B-cell trafficking to the CNS in neuropathies.

Meya et al, have shown that immune cell homing and localisation in the CSF are possible during HIV and associated cryptococcosis co-infection. In this study, CD4 T-cell frequency was low at onset of HIV-associated cryptococcosis among individuals who later developed cryptococcal IRIS. The onset of IRIS was associated with the later increase in the CD4 T-cell frequency in the CSF. A study in a similar setting showed a wide spectrum of pro-inflammatory protein profile (IFN-γ, IL-1β, TNF-α) and anti-inflammatory proteins (IL-10, granulocyte monocytes/macrophage colony stimulating factor (GM-CSF)) being upregulated in CSF during cryptococcal infection. This array of immune modulators in CSF may show the importance of cellular trafficking or passive entry of vital molecules to the CSF in response to intrathecal stimulations. Some of the markers expressed could exacerbate inflammation and immune activation of host damage responses that could have a negative influence on cryptococcal disease and treatment outcomes. Studies in cancer therapy, organ transplant recipients and chronic inflammatory disease conditions show that regulation of these chemokine receptor expression (CXCR3 and CXCR5) by blocking their ligand interaction modulated host recovery. Thus, evaluation of the role and relevance of these B-cell chemokine receptors expression induction (CXCR3, CXCR5, CCR7 and CCR3) in CSF and blood may advance our understanding of HIV and cryptococcosis pathogenesis and potentially treatment outcome paradigms for translation.

12 | FACTORS LINKED TO FATAL CRYPTOCOCCUS CENTRAL NERVOUS SYSTEM INFECTION

Among patients with HIV-associated cryptococcal meningitis where C neoformans sensu lato and interspecies hybrids cause most disease, inconsistent variables (Figure 3D) that influence disease outcome have been reported including early ART initiation among HIV and ART naïve subjects. The high fungal burden and altered mental status at cryptococcal meningitis diagnosis coupled with the slow fungal clearance following antifungal therapy. The prevalence of seizures at diagnosis and the incidence seizures during the course of treatment and follow-up among individuals with above 96 000 fungal colony-forming units that is 3-four fold higher in those with seizures compared to those without seizures. Limited oxygen blood carrying capacity (anaemia) potentially leading to low brain oxygen saturation, hypoxia. Although amphotericin B is known to suppress erythropoietin, a factor that may influence the extent of anaemia in cryptococcosis sequelae. Surprisingly, amphotericin B-induced anaemia is not associated with cryptococcosis cause fatal in first two and half months of cryptococcosis diagnosis. And fibrosis among cases of cryptococcal meningitis may influence onset and the extent of intracranial pressure build up, hypoxia, brain infarction and antifungal drug penetration. Interestingly, these variables and factors associated with poor cryptococcosis outcome are reported independent of each other within similar large cohorts of HIV-associated cryptococcal meningitis. This implies that multiple or slightly independent pathways drive host pathology. Thus, advances to alter poor survival outcomes could require deliberate effects to combine multiple factors in combined interventions targeting multiple pathways in the host.

In addition, an ineffectual immune system with a skewed Th-2 immune response has been associated with poor disease outcomes. The Th-2 immune response is seen to inhibit activation of Cryptococcus-specific antifungal pro-inflammatory cytokine responses, thus impairing fungal clearance. And the high frequency of pro-inflammatory cytokines responses (IFN-γ, TNF-α and IL-12) coupled with a high frequency of CSF infiltrating white blood cells after ART initiation is associated with a risk of cryptococcal meningitis-immune reconstitution inflammatory syndrome (CM-IRIS).
But, predominance of a pro-inflammatory cytokine response alone is postulated to work in synergy with antifungal treatment to enhance fungal clearance.\textsuperscript{20,21} Conversely, in animal models of cryptococcal infection, animals that produce antibodies specific to Cryptococcus virulence factors including melanin, urease and polysaccharide capsule after exposure to pulmonary cryptococcal antigens demonstrate higher numbers of long-term survivors. This was observed following a challenge with a live lethal dose of Cryptococcus in experimental animals.\textsuperscript{61,64,144–146} Similarly, high expression of PD-1 on plasmablasts/plasma cells is linked to host survival among patients with cryptococcosis.\textsuperscript{24}

Thus, survival in HIV and cryptococcosis co-infection is associated with higher expression of pro-inflammatory cytokine responses (IFN-\(\gamma\), TNF-\(\alpha\) and IL-6) and corresponding higher influx of white blood cells that infiltrate the cerebrospinal fluid.\textsuperscript{20,21,49} Although unregulated expression of these cytokines is linked with onset of IRIS, their production seems to function in synergy with antifungal treatment to enhance fungal clearance\textsuperscript{20,21,49} while downregulation of pro-inflammatory cytokine responses is associated with poor control of fungal antigens and mortality.\textsuperscript{50} At cryptococcosis diagnosis, individuals at risk of IRIS sequelae have higher expression of IL-6 and IL-10.\textsuperscript{147} In addition, these individuals have higher expression of anti-glucuronoxylomannan antibodies\textsuperscript{148} and overexpression of pro-inflammatory cytokines.\textsuperscript{97,149} Moreover, IL-6 expression, one of the upregulated pro-inflammatory cytokine, is known to influence the capability of B cells to proliferate.\textsuperscript{150} Thus, possibly linking B cells to the onset of IRIS.

**13 | CONCLUSION AND PERSPECTIVES**

Despite four decades of HIV era and advances to treat those infected with optimal therapy, cryptococcal meningitis remains a significant contributor of death among HIV-infected adults especially in sub-Saharan Africa. Consolidated new insights show that the HIV and cryptococcal meningitis-associated poor survival outcome factors are associated with fungal induced neuropathies related to the inducers of seizures, altered mental status, brain tissue fibrosis and brain hypoxia and potentially the involved cryptococcal species. In addition, altered immune response involving PD-1/PD-L1 pathway may dysregulate immune activation to influence inflammation and impact on brain fibrosis and brain infarction. And dysregulated erythropoiesis associated with prevalent anaemia together with induced fibrosis may influence hypoxia and brain infarction. These insights come at a time of unknown immunological target to prevent HIV-associated cryptococcal meningitis and adequate therapy to prevent mortality. Together, the eluded factors and underlying mechanisms are hypotheses generating and will guide further studies to finding targets to prevent infection or adequate therapy to prevent mortality. Interventions like the use of supplemental oxygen, blood transfusion to boost blood oxygen carrying capacity and the use of anti-PD-1/PD-L1 blockers to restore appropriate immune reconstitution may be valuable advances to alter poor treatment outcome.

**14 | LIMITATIONS**

Our findings are without important limitations that our discussion is based on online published literature generalised to Cryptococcus in the setting of HIV-associated cryptococcosis. However, individual Cryptococcus species may influence infection or disease recovery differently requiring species identification to define species-specific pathologies and treatment outcome for clinical relevance. This is important because Cryptococcus still causes substantial morbidity and mortality that may require different treatment strategies to prevent residual 10%-20% of cryptococcosis-related deaths occurring with optimal use of antifungals. And that, although we conducted a wide literature search, we might have left out relevant literature. And some deductions are based on a few articles on the subject matter that may limit generalisation.

**ACKNOWLEDGEMENTS**

We thank Barbara Castelnuovo, Stephen Okoboi, Aidah Nanvuma, from Infectious Diseases Institute, Research Capacity Building Unit, for supporting the training programme.

**CONFLICT OF INTEREST**

Nothing to disclose.

**AUTHOR CONTRIBUTION**

Samuel Okurut: Conceptualization (lead); Data curation (lead); Formal analysis (lead); Funding acquisition (lead); Investigation (lead); Methodology (lead); Project administration (lead); Resources (lead); Software (lead); Supervision (lead); Validation (lead); Visualization (lead); Writing-original draft (lead); Writing-review & editing (lead). Joseph Olobo: Conceptualization (supporting); Data curation (supporting); Formal analysis (supporting); Investigation (supporting); Methodology (supporting); Project administration (supporting); Resources (supporting); Software (supporting); Supervision (supporting); Validation (supporting); Visualization (supporting); Writing-original draft (supporting); Writing-review & editing (supporting). David Boulware: Conceptualization (equal); Data curation (equal); Formal analysis (supporting); Funding acquisition (supporting); Investigation (equal); Methodology (supporting); Project administration (equal); Resources (supporting); Software (supporting); Supervision (supporting); Validation (supporting); Visualization (equal); Writing-original draft (equal); Writing-review & editing (equal). David Meya: Conceptualization (equal); Data curation (equal); Formal analysis (supporting); Funding acquisition (supporting); Investigation (equal); Methodology (equal); Project administration (equal); Resources (supporting); Software (supporting); Supervision (equal); Validation (equal); Visualization (equal); Writing-original draft (equal); Writing-review & editing (equal).

**ETHICAL CONSIDERATIONS**

Nothing to disclose.

**ORCID**

Samuel Okurut [https://orcid.org/0000-0002-9292-8687](https://orcid.org/0000-0002-9292-8687)
REFERENCES

1. Lee SC, Casadevall A, Dickson DW. Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. Am J Pathol. 1996;148(4):1267-1274.

2. Esher SK, Zaragoza O, Alspaugh JA. Cryptococcal pathogenic mechanisms: A dangerous trip from the environment to the brain. Mem Inst Oswaldo Cruz. 2018;113(7):1-15. https://doi.org/10.1590/0074-02760180057

3. Nielsen K, Cox GM, Litvintseva AP, et al. Cryptococcus neoformans α strains preferentially disseminate to the central nervous system during coinfection. Infect Immun. 2005;73(8):4922-4933. https://doi.org/10.1128/IAI.73.8.4922-4933.2005

4. May RC, Stone NRH, Wiesner DL, Bicanic T, Nielsen K, Georges S. Geographically Structured Populations of Cryptococcus neoformans Variety grubii in Asia Correlate with HIV Status and Show a Clonal Population Structure. PLoS One. 2013;8(9):1-14. https://doi.org/10.1371/journal.pone.0072222

5. Litvintseva AP, Lin X, Templeton I, Heitman J, Mitchell TG. Many globally isolated AD hybrid strains of Cryptococcus neoformans originated in Africa. PLoS Pathog. 2007;3(8):1109-1117. https://doi.org/10.1371/journal.ppat.0030114

6. Khayhan K, Hagen F, Pan W, et al. Geographically Structured Populations of Cryptococcus neoformans Variety grubii in Asia Correlate with HIV Status and Show a Clonal Population Structure. PLoS One. 2013;8(9):1-14. https://doi.org/10.1371/journal.pone.0072222

7. Herkert PF, Meis JF, Lucca de Oliveira Salvador G, et al. Molecular characterization and antifungal susceptibility testing of Cryptococcus neoformans sensu stricto from southern Brazil. J Med Microbiol. 2018;67(4):560-569. https://doi.org/10.1099/jmm.0.006968

8. Kaucharoen S, Ngaumkulungroj P, Firacative C, et al. Molecular epidemiology reveals genetic diversity amongst isolates of the Cryptococcus neoformans/C gattii species complex in Thailand. PLoS Negl Trop Dis. 2013;7(7):1-9. https://doi.org/10.1371/journal.pntd.0002297

9. Van Wyk M, Govender NP, Mitchell TG, Litvintseva AP. Multilocus sequence typing of serially collected isolates of cryptococcus from HIV-infected patients in South Africa. J Clin Microbiol. 2014;52(6):1921-1931. https://doi.org/10.1128/JCM.03177-13

10. Nyazika TK, Hagen F, Pan W, et al. Cryptococcus neoformans Population diversity and clinical outcomes of HIV-associated cryptococcal meningitis: Implications for improving outcomes. Clin Infect Dis. 2014;58(5):736-745. https://doi.org/10.1093/cid/cit794

11. Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. N Engl J Med. 2013;370(26):2487-2498. https://doi.org/10.1056/NEJMo1312884

12. Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis. MBio. 2017;8(6):e00610-10. https://doi.org/10.1128/mBio.00610-17

13. Boulaye DR, Meya DB, Muoza C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487-2498. https://doi.org/10.1056/NEJMo1312884

14. Miglia KJ, Govender NP, Rossouw J, et al. Analyses of pediatric isolates of Cryptococcus neoformans from South Africa. J Clin Microbiol. 2011;49(1):307-314. https://doi.org/10.1128/JCM.01277-10

15. Hansakon A, Mutthakalin P, Ngamshulangroj P, Chayakulkeeree M. Angkasekwina P Cryptococcus neoformans and Cryptococcus gattii clinical isolates from Thailand display diverse phenotypic interactions with macrophages. Virulence. 2019;10(1):26-36. https://doi.org/10.1080/21505594.2018.1556150

16. Fernandes KE, Dwyer C, Campbell DT, Carter DA. Complex in capsule and cell size following growth under capsule. mSphere. 2016;1(6):1-13. https://doi.org/10.1128/mSphere.00350-16. Editor.

17. Hagen F, Hare Jensen R, Meis JF, Arendrup MC. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark. Mycoses. 2016;59(9):576-584. https://doi.org/10.1111/myc.12507

18. Nyazika TK, Hagen F, Meis JF, Robertson JV. Cryptococcus tetragnathi as a major cause of cryptococcal meningitis among HIV-infected individuals in Harare, Zimbabwe. J Infect. 2016;72(6):745-752. https://doi.org/10.1016/j.jinf.2016.02.018

19. Pirofski LA, Casadevall A. Immune-mediated damage completes the parabola: Cryptococcus neoformans pathogenesis can reflect the outcome of a weak or strong immune response. MBio. 2017;8(6):6-10. https://doi.org/10.1128/mBio.02063-17

20. Boulaye DR, Meya DB, Muoza C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487-2498. https://doi.org/10.1056/NEJMo1312884

21. Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: Implications for improving outcomes. Clin Infect Dis. 2014;58(5):736-745. https://doi.org/10.1093/cid/cit794

22. Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. N Engl J Med. 2018;378(11):1004-1017. https://doi.org/10.1056/NEJMo1710922

23. Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873-881. https://doi.org/10.1016/S1473-3099(17)30243-8

24. Okurut S, Meya DB, Kwanga F, et al. B cell compartmentalization in Blood and Cerebrospinal Fluid of HIV-Infected Ugandans with Cryptococcal Meningitis. PLoS Medicine. 2010;7(12):1-14. https://doi.org/10.1371/journal.pmed.1000384

25. Chen J, Zhang R, Shen Y, et al. Serum cryptococcal antigen titre as a diagnostic tool and a predictor of mortality in HIV-infected patients with cryptococcal meningitis. HIV Med. 2018;69-73. https://doi.org/10.1111/hiv.12679

27. Elsegényi W, Marr KA, Williamson PR. Immunology of cryptococcal infections: Developing a rational approach to patient therapy. Front Immunol. 2018;9:651. https://doi.org/10.3389/fimmu.2018.00651

28. Suleman A, Padmore R, Faught C, Cowan J. Disseminated cryptococcal infection in a patient with treatment-naïve chronic lymphocytic leukemia (CLL). IDCases. 2019;17:e00566. https://doi.org/10.1016/j.idcr.2019.e00566
29. Kenneth S, Bangdiwala AS, Kwisera R, et al. Symptomatic cryptococcal antigenemia presenting as early cryptococcal meningitis with negative CSF analysis. *Clin Infect Dis*. 2018;68(12):2094–2098. https://doi.org/10.1093/cid/ciy817

30. Ellis J, Bangdiwala AS, Cresswell FV, et al. The changing epidemiology of HIV-associated adult meningitis, Uganda 2015–2017. *Open Forum Infect Dis*. 2019;6(10):2015-2017. https://doi.org/10.1093/ofid/ofz419

31. Rolfo MA, Tengsupakul S, Mossel EC, et al. Epidemiology of meningitis in an HIV-infected Ugandan cohort. *Am J Trop Med Hyg*. 2015;92(2):274-279. https://doi.org/10.4269/ajtmh.14-0452

32. Meya D, Rajasingham R, Nalintya E, Tenforde M, Jarvis JN. Preventing cryptococcosis-shifting the paradigm in the era of highly active antiretroviral therapy. *Curr Trop Med Rep*. 2015;2(2):81-89. https://doi.org/10.1007/s40475-015-0045-z

33. Fisher JF, Valencia-Rey PA, Davis WB. Pulmonary cryptococcosis. *Curr Clin Microbiol Rep*. 2015;107(5):E66. https://doi.org/10.1542/peds.107.5.e66

34. Datta K, Pirofski LA. Towards a vaccine for Cryptococcus neoformans: Principles and caveats. *FEMS Yeast Res*. 2006;6(4):525-536. https://doi.org/10.1111/j.1576-1347.2006.00073.x

35. Wake RM, Govender NP, Omar T, et al. Cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukaemia. *Leuk Lymphoma*. 2013;54(3):643-645. https://doi.org/10.3109/10428170.2012.710801

36. Pastick KA, Bangdiwala AS, Abassi M, et al. Seizures in human immunodeficiency virus-associated cryptococcal meningitis: Predictors and outcomes. *Open Forum Infect Dis*. 2019;6(11):1-7. https://doi.org/10.1093/ofid/ofz478

37. Diehl JW, Hullsiekh KH, Okirwot M, et al. Cerebral oximetry for detecting high-mortality risk patients with cryptococcal meningitis. *Open Forum Infect Dis*. 2018;5(6):1-7. https://doi.org/10.1093/ofid/ofy105

38. Sabiiti W, Robertson E, Beale MA, et al. Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis. *Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis*. *Clin Invest*. 2014;124(5):2000-2008. https://doi.org/10.1172/JCI72950

39. Goldman DL, Khine H, Abadi J, et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. *Pediatrics*. 2001;107(5):E66. https://doi.org/10.1542/peds.107.5.e66

40. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence ofid/ofz419

41. Miller GP. The immunology of cryptococcal disease. *Semin Respir Infect*. 1986;1(1):45-52.

42. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. *AIDS*. 2009;23(4):525-530. https://doi.org/10.1097/QAD.0b013e32832f2ac

43. Hagen F, Illnait-Zaragozí M-T, Meis JF, et al. Extensive genetic diversity within the Dutch clinical *Cryptococcus neoformans* population. *J Clin Microbiol*. 2012;50(6):1918-1926. https://doi.org/10.1128/JCM.06750-11

44. Chen SCA, Meyer W, Sorrell TC. Cryptococcus gattii infections. *Clin Microbiol Rev*. 2014;27(4):980-1024. https://doi.org/10.1128/CMR.00126-13

45. George IA, Santos CAQQ, Olsen MA, Powderly WG. Epidemiology of cryptococcosis and cryptococcal meningitis in a large retrospective cohort of patients after solid organ transplantation. *Open Forum Infect Dis*. 2017;4(1):1-7. https://doi.org/10.1093/ofid/ofx004

46. Gassiep I, McDougall D, Douglas J, Francis R, Playford EG. Cryptococcal infections in solid organ transplant recipients over a 15-year period at a state transplant center. *Transpl Infect Dis*. 2017;19(1):e12639. https://doi.org/10.1111/tid.12639

47. Agrawal C, Sood V, Kumar A, Raghavan V. Cryptococcal infection in transplant kidney manifesting as chronic allograft dysfunction. *Indian J Nephrol*. 2017;27(5):392-394. https://doi.org/10.4103/ijn.JN_298_16

48. Gundacker ND, Baddley JW. Fungal infections in the era of biologic therapies. *Curr Clin Microbiol Rep*. 2015;2(2):76-83. https://doi.org/10.1007/s40458-015-0018-y

49. Jarvis JN, Casazza JP, Stone HH, et al. The phenotype of the cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. *J Infect Dis*. 2013;207(12):1817-1828. https://doi.org/10.1093/infdis/jit099

50. Tenforde MW, Scrivern JE, Harrison TS, Jarvis JN. Immune correlates of HIV-associated cryptococcal meningitis. *PLoS Pathog*. 2017;13(3):4-11. https://doi.org/10.1371/journal.ppat.1006207

51. Subramaniam K, French N, Pirofski L-AA. Cryptococcus neoformans-reactive and total immunoglobulin profiles of human immunodeficiency virus-infected and uninfected Ugandans. *Clin Diag Lab Immunol*. 2005;12(10):1168-1176. https://doi.org/10.1128/CDLI.12.1168-1176.2005

52. Marchand T, Revest M, Tattevin P, et al. Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukaemia. *Leuk Lymphoma*. 2013;54(3):643-645. https://doi.org/10.3109/10428170.2012.710801

53. Sanchez-Ojapungre I, Isern-Seguera I, Chico-Chumillas C, Javaloyas-de-Morlius M. Cryptococcus neoformans meningoencephalitis in a patient treated with rituximab. *Med Clin (Barc)*. 2009;133(4):157-158. https://doi.org/10.1016/j.medcl.2008.09.036

54. Rohatgi S, Golih S, Kuniholm MH, et al. FC gamma receptor IIIA polymorphism and risk for HIV-associated cryptococcal disease. *MBio*. 2013;4(5):e00573-e613. https://doi.org/10.1128/mBio.00573 -13

55. Meletiadis J, Walsh TJ, Choi EH, et al. Study of common functional genetic polymorphisms of FCGR2A, 3A and 3B genes and the risk for cryptococcus in HIV-uninfected patients. *Med Mycol*. 2007;45(6):513-518. https://doi.org/10.1080/13693780701390140

56. Hu X-P, Wu J-Q, Zhu L-P, et al. Association of FC γ receptor IIb polymorphism with HIV-associated cryptococcal meningitis in HIV-uninfected Chinese patients. *PLoS One*. 2012;7(8):1-6. https://doi.org/10.1371/journal.pone.0042439

57. Mukamere L, Nielsen K. Adaptive Immunity to Cryptococcus neoformans Infections. *J Fungi*. 2017;3(4):64. https://doi.org/10.3390/jof3040064

58. Nelson BN, Hawkins AN, Wozniak KL. Pulmonary macrophage and dendritic cell responses to Cryptococcus neoformans. *Front Cell Infect Microbiol*. 2020;10(Feb):37. https://doi.org/10.3389/fcimb.2020.00037

59. Beale MA, Sabiiti W, Robertson EJ, et al. Genotypic diversity is associated with clinical outcome and phenotype in cryptococcal meningitis across southern Africa genotypic diversity is associated with clinical outcome and phenotype in cryptococcal meningitis across southern Africa. *PLoS Negl Trop Dis*. 2015;9(6):e0003847. https://doi.org/10.1371/journal.pntd.0003847

60. Litvintseva AP, Mitchell TG. Population genetic analyses reveal the African origin and strain variation of Cryptococcus neoformans var. grubii. *PLoS Pathog*. 2012;8(2):8-11. https://doi.org/10.1371/journal.ppat.1002495

61. May RC, Stone NRH, Wiesner DL, Bicanic T, Nielsen K. Cryptococcus : from environmental saprophyte to global pathogen. *Nat Publ Gr*. 2015;14(2):106-117. https://doi.org/10.1038/nrmicro.2015.6
62. Santiago-Tirado FH, Onken MD, Cooper JA, Klein RS, Doering TL. Trojan horse translocate contributes to blood-brain barrier crossing of a eukaryotic pathogen. MBio. 2017;8(1):e02183-16. https://doi.org/10.1128/mBio.02183-16

63. Veenstra M, León-rivera R, Li M, Gama L, Clements JE. Mechanisms of CNS viral seeding by HIV+ CD14+ CD16+ monocytes: Establishment and reseeding of viral reservoirs contributing to HIV-associated neurocognitive disorders. MBio. 2017;8(5):1-15.

64. Voelz K, May RC. Cryptococcal interactions with the host immune system. Eukaryot Cell. 2010;9(6):835-846. https://doi.org/10.1128/EC.00039-10

65. Shourian M, Qureshi ST. Resistance and tolerance to cryptococcal infection: An intricate balance that controls the development of disease. Front Immunol. 2019;10:1-11. https://doi.org/10.3389/fimmu.2019.00066

66. Meya DB, Okurut S, Zziwa G, et al. Cellular immune activation in and T cell subset balance in cryptococcal meningitis. J Cell Biochem. 2018;119(4):3044-3057. https://doi.org/10.1002/jcb.26432

67. Cubas RA, Mudd JC, Savoye A-L, et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. MBio. 2013;4(4):494-499. https://doi.org/10.1128/mBio.00310.2013

68. Thibult M-L, Mamessier E, Gertner-Dardenne J, et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol. 2013;25(2):129-137. https://doi.org/10.1093/intimm/dxs098

69. Jing W, Li M, Zhang Y, et al. PD-1/PD-11 blockade in non-small-cell lung cancer therapy. Onco Targets Ther. 2016;9:489-502. https://doi.org/10.2147/OTT.S94993

70. Rao M, Valentin D, Dodoo E, Zumla A, Maeurer M. International Journal of Infectious Diseases Anti-PD-1 / PD-L1 therapy for infection. Nat Med. 2015;21(10):1597-1606. https://doi.org/10.1038/nmed.2016.027

71. Ilcus C, Bagacean C, Tempescul A, et al. Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. Onco Targets Ther. 2017;10:2349-2363. https://doi.org/10.2147/OTT.S133385

72. Buermann A, Römermann D, Baars W, Hundrieser J, Klemptner J, Schwinzer R. Inhibition of B-cell activation and antibody production by triggering inhibitory signals via the PD-1/PD-ligand pathway. Xenotransplantation. 2016;23(5):347-356. https://doi.org/10.1111/xen.12261

73. Roussey JA, Viglianti SP, Teitz-Tennenbaum S, Olszewski MA, Oehler LS, Osterholzer JJ. Anti-PD-1 antibody treatment promotes clearance of persistent cryptococcal lung infection in mice. J Immunol. 2017;199(10):3535-3546. https://doi.org/10.4049/jimmunol.1700840

74. Lázár-Molnár E, Scandiuzzi L, Basu I, et al. Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. ElBioMedicine. 2017;17:30-44. https://doi.org/10.1016/j.ibio.2017.02.004

75. Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28(6):1280-1288. https://doi.org/10.1038/leu.2013.355

76. Grzywnowicz M, Zaleska J, Mertens D, et al. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One. 2012;7(4):e35178.

77. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13(7):2151-2157. https://doi.org/10.1158/1078-0432.CCR-06-2746

78. Che Y-M, Zhang Y, Li M, Li X-P, Zhang L-L. In vitro and in vivo effect of PD-1/PD-L1 blockade on microglia/macrophage activation and T cell subset balance in cryptococcal meningitis. J Cell Biochem. 2018;119(4):3044-3057. https://doi.org/10.1002/jcb.26432

79. Murdock BJ, Teitz-Tennenbaum S, Chen G-H, et al. Early or late IL-10 blockade enhances Th1 and Th17 effector responses and promotes fungal clearance in mice with cryptococcal lung infection. J Immunol. 2014;193(8):4107-4116. https://doi.org/10.4049/jimmunol.1400650

80. Bankó Z, Pozsgay J, Szili D, et al. Induction and differentiation of IL-10-producing regulatory B cells from healthy blood donors and rheumatoid arthritis patients. J Immunol. 2017;198(4):1512-1520. https://doi.org/10.4049/jimmunol.1600218

81. Clatworthy MR. B-cell regulation and its application to transplantation. Transpl Int. 2014;27(2):117-128. https://doi.org/10.19263/REDAI.9916.12

82. Mauri C, Menon M. Human regulatory B cells in health and disease: therapeutic potential. J Clin Invest. 2017;127(3):772-779. https://doi.org/10.1172/JCI85113

83. Liu B-S, Cao Y, Huizinga TW, Hafer DA, Toes REM. TLR-mediated STAT3 and ERK activation controls IL-10 secretion by human B cells. Eur J Immunol. 2014;44(7):2121-2129. https://doi.org/10.1002/eji.201344341

84. Zhang Y, Liang C. Innate recognition of microbial-derived signals in immunity and inflammation. Sci China Life Sci. 2016;59(12):1210-1217. https://doi.org/10.1007/s11427-016-0325-6

85. Chen GY, Núñez G. Sterile inflammation: Sensing and reacting to damage. Nat Rev Immunol. 2010;10(12):826-837. https://doi.org/10.1038/nri2873

86. Kozono Y, Abe R, Kozono H, Kelly RG, Azuma T, Holers VM. Cross-linking CD21/CD35 or CD19 increases both B1-7 and B1-2 expression on murine splenic B cells. J Immunol. 1998;160(4):1565-1572.

87. Vos Q, Lees A, Wu QZ, Snapper CM, Mond JJ. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immune Rev. 2000;176:154-170. https://doi.org/10.1034/j.1600-065X.2000.00607.x

88. Maslilamani M, Kassahn D, Mikkat S, Glocker MO, Illges H. B cell activation leads to shedding of complement receptor type II (CR2/CD21). Eur J Immunol. 2003;33(9):2391-2397. https://doi.org/10.1002/eji.200323843

89. Zeissig S, Blumberg RS. Analizing antigen recognition by natural killer T cells. Methods Mol Biol. 2019;1988:439-453. https://doi.org/10.1007/978-1-4939-9450-2_30

90. Lian J, Luster AD. Orchestrates the Generation of Adaptive Immune Responses. Curr Opin Cell Biol. 2015;36:1-6. https://doi.10.1016/j.cub.2015.05.003. Chemokine-guided.

91. Kowarik MC, Cepok S, Sellner J, et al. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation. 2012;9(1):1-11.

92. Sokol CL, Luster AD. The chemokine system in innate immunity. Cold Spring Harb Perspect Biol. 2015;7(5):1-20. https://doi.org/10.1101/cshperspect.a016303

93. Chang CC, Omarjee S, Lim A, et al. Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptoco-cosis-associated immune reconstitution inflammatory syndrome. J Infect Dis. 2013;208:1604-1612. https://doi.org/10.1093/infdis/jit388

94. Tenor JL, Oehlers SH, Yang JL, Tobin DM, Perfect JR. Live imaging of host-parasite interactions in a zebrafish infection model reveals cryptococcal determinants of virulence and central nervous system invasion. MBio. 2015;6(5):1-11. https://doi.org/10.1128/mbio.01425-15

95. Barcia C. Gial-mediated inflammation underlying parkinsonism. Scientific (Cairo). 2013;2013:357805. https://doi.org/10.1155/2013/357805
96. Meya DB, Okurut S, Ziwa G, Cosse S, Boulware DR, Janoff EN. HIV-associated cryptococcal immune reconstitution inflammatory syndrome is associated with aberrant T cell function and increased cytokine responses. J Fungi (Basel). 2019;5(2):42. https://doi.org/10.3390/jf5020042

97. Meya D, Okurut S, Ziwa G, et al. Monocyte phenotype and IFN-γ inducible cytokine responses are associated with cryptococcal immune reconstitution inflammatory syndrome. J Fungi. 2019;3(28. https://doi.org/10.3390/jf3020028

98. Jarvis JN, Harrison TS. Understanding causal pathways in cryptococcal meningitis immune reconstitution inflammatory syndrome. J Infect Dis. 2018;219:344-346. https://doi.org/10.1093/infdis/jiy448

99. Baiyinja A, Okurut S, Nabatanzi R, et al. Longitudinal changes in Cd4(+), Cd8(+) T cell phenotype and activation marker expression following antiretroviral therapy initiation among patients with cryptococcal meningitis. J Fungi (Basel). 2019;5(3):63. https://doi.org/10.3390/jf5030063

100. Liu F, Dai W, Li C, et al. Role of IL-10-producing regulatory B cells in modulating T-helper cell immune responses during silica-induced lung inflammation and fibrosis. Sci Rep. 2016;6(1):1-12.

101. Geng Y, Liu X, Liang J, et al. PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight. 2019;4(6). https://doi.org/10.1172/jci.insight.125326

102. Shimoda Y, Ohtomo S, Arai H, Ohtoh T, Tominaga T. Subarachnoid small vein occlusion due to inflammatory fibrosis-a possible mechanism for cerebellar infarction in cryptococcal meningoenephelitis: a case report. BMC Neuro. 2017;17(1):157. https://doi.org/10.1186/s12883-017-0934-y

103. Hung C-W, Chang W-N, Kung C-T, et al. Predictors and long-term outcome of seizures in human immuno-deficiency virus (HIV)-negative cryptococcal meningitis. BMC Neuro. 2014;14(1):1-8. https://doi.org/10.1186/s12883-014-0208-x

104. Grahl N, Cramer RA. Regulation of hypoxia adaptation: An over-looked virulence attribute of pathogenic fungi? Med Mycol. 2010;48(1):1-15. https://doi.org/10.1080/13693780902947342

105. Izycka-Swieszewska E, Zółtowska A, Rzepko R, Gross M, Borowska-Lehman J. Vasculopathy and amyloid beta reactivity in small vein occlusion due to inflammatory fibrosis-a possible mechanism for cerebellar infarction in cryptococcal meningoenephelitis: a case report. BMC Neuro. 2017;17(1):157. https://doi.org/10.1186/s12883-017-0934-y

106. Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in the marginal zone and beyond. J Exp Med. 2010;217(1):175-182.

107. Boulware D, Bonham S, Meya D, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis. 2010;202(6):962-970. https://doi.org/10.1086/655785

108. Kardava L, Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med. 2008;205(8):1797-1805. https://doi.org/10.1084/jem.20072683

109. Garg H, Joshi A. Host and viral factors in HIV-mediated bystander apoptosis. Viruses. 2017;9(8):1-23. https://doi.org/10.3390/v9080237

110. Lenassi M, Cagney G, Liao M, et al. HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic. 2010;11(1):110-122. https://doi.org/10.1111/j.1600-0854.2009.01006.x

111. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A Regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008;28(5):639-650. https://doi.org/10.1016/j.immuni.2008.03.017

112. Garraud O, Borhis G, Badr G, et al. Revisiting the B-cell compartment in mouse and humans: more than one B-cell subset exists in the marginal zone and beyond. BMC Immunol. 2012;13(1):63. https://doi.org/10.1186/1471-2172-13-63

113. Louis AG, Agrawal S, Gupta S. Analysis of subsets of B cells, Breg, CD4Treg and CD8Treg cells in adult patients with primary selective IgM deficiency. Am J Clin Exp Immunol. 2016;5(1):21-32.

114. Kardava L, Moir S. B-cell abnormalities in HIV-1 infection. Curr Opin HIV AIDS. 2019;14(4):240-245. https://doi.org/10.1097/COH.0000000000000547

115. Moir S, Fauci AS. Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. Immunol Rev. 2013;254(1):207-224.

116. Finn EE, Janoff J, Rahkola J, et al. Local and systemic humoral responses to cryptococcal meningitis in patients with AIDS. Top Antivir Med. 2015;23:378-379.

117. Hlupeni A, Nakouzi A, Wang T, et al. Antibody responses in HIV-infected viremic individuals. Pathol Biol (Paris). 2017;59(5):399-403. https://doi.org/10.1016/j.patbio.2016.09.007

118. Wilson EMP, Art E. Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. JFungi (Basel). 2015;2015:6710-6715. https://doi.org/10.3390/jf5020042

119. Han J, Sun LL, Fan X, et al. Review role of regulatory B cells in neurom immunologic disorders. J Neurosci Res. 2016;701:693-701.

120. Moir S, Fauci AS. B-cell responses to HIV infection. Immunol Rev. 2017;275(1):33-48.

121. Dai Y-C, Zhong J, Xu J-F. Regulatory B cells in infectious disease roimmunologic disorders. J Neurosci Res. 2017;275(1):33-48.

122. Dai Y-C, Zhong J, Xu J-F. Regulatory B cells in infectious disease roimmunologic disorders. J Neurosci Res. 2017;275(1):33-48.

123. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A Regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008;28(5):639-650. https://doi.org/10.1016/j.immuni.2008.03.017

124. Garraud O, Borhis G, Badr G, et al. Revisiting the B-cell compartment in mouse and humans: more than one B-cell subset exists in the marginal zone and beyond. BMC Immunol. 2012;13(1):63. https://doi.org/10.1186/1471-2172-13-63

125. Louis AG, Agrawal S, Gupta S. Analysis of subsets of B cells, Breg, CD4Treg and CD8Treg cells in adult patients with primary selective IgM deficiency. Am J Clin Exp Immunol. 2016;5(1):21-32.

126. Kardava L, Moir S. B-cell abnormalities in HIV-1 infection. Curr Opin HIV AIDS. 2019;14(4):240-245. https://doi.org/10.1097/COH.0000000000000547

127. Moir S, Fauci AS. Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. Immunol Rev. 2013;254(1):207-224.

128. Finn EE, Janoff J, Rahkola J, et al. Local and systemic humoral responses to cryptococcal meningitis in patients with AIDS. Top Antivir Med. 2015;23:378-379.

129. Hlupeni A, Nakouzi A, Wang T, et al. Antibody responses in HIV-infected patients with advanced immunosuppression and asymptomatic cryptococcal antigenemia. Open Forum Infect Dis. 2019;6(1):ofy333.

130. Wilson EMP, Art E. Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunol Rev. 2013;254:343-354.

131. Bang J, Sun LL, Fan X, et al. Review role of regulatory B cells in neurom immunologic disorders. J Neurosci Res. 2016;701:693-701.

132. Negi N, Das BKCN. Not an immunoprivileged site anymore but a virtual secondary lymphoid organ. Int Rev Immunol. 2018;37(1):57-68.
133. Pereira JP, Kelly LM, Jason JGC. Finding the right niche: B-cell migration in the early phases of T-dependent antibody responses. Int Immunol. 2010;22(6):413-419.

134. Payne D, Drinkwater S, Baretto R, Duddridge M, Browning MJ. Expression of chemokine receptors CXCR4, CXCR5 and CCR7 on B and T lymphocytes from patients with primary antibody deficiency. Clin Exp Immunol. 2009;156(2):254-262.

135. Beauvillain C, Cunin P, Doni A, et al. CCR7 is involved in the migration of neutrophils to lymph nodes. Blood. 2011;117(4):1196-1204.

136. Yu Q, Cheng Y, Wang Y, et al. Aberrant humoral immune response in neurosyphilis: CXCL13/CXCR5 play a pivotal role for B-cell recruitment to the cerebrospinal fluid. J Infect Dis. 2017;216(5):534-544. https://doi.org/10.1093/infdis/jix233

137. Chang CC, Omarjee S, Lim A, et al. Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis. Associated immune reconstitution inflammatory syndrome. J Infect Dis. 2013;208(10):1604-1612. https://doi.org/10.1093/infdis/jit388

138. Hickman HD, Reynoso GV, Nguodianama BF, et al. CXCR3 chemokine receptor enables local CD8+ T cell migration for the destruction of virus-infected cells. Immunity. 2016;42(3):524-537.

139. Song DJ, Shim MH, Lee N, Yoo Y, Cheung JT. CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis. Allergy Asthma Immunol Res. 2017;9(4):360-367.

140. Zhou CY, Wen Q, Chen XJ, et al. Human CD8+ T cells transduced with an additional receptor bispecific for both Mycobacterium tuberculosis and HIV-1 recognize both epitopes. J Cell Mol Med. 2016;20(10):1984-1998.

141. Chiniak RJ, Janakiram M, Chen F, Chen W, Kaplan M, Zang X. New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci. 2015;36(9):587-595.

142. Tugume L, Morawski BM, Abassi M, et al. Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis. HIV Med. 2017;18(1):13-20.

143. Macgregor ROBR, Bennett JE, Ersliev AJ. Erythropoietin concentration in amphotericin B-induced anemia. Vic Reports. 2013;39:543-553.

144. Martinez LR, Casadevall A. Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun. 2005;73(10):6350-6362.

145. McClelland EE, Nicola AM, Prados-Rosas R, Casadevall A. Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J Clin Invest. 2010;120(4):1355-1361.

146. Coelho C, Casadevall A. Cryptococcal therapies and drug targets: the old, the new and the promising. Cell Microbiol. 2016;18(6):792-799.

147. Yoon HA, Nakouzi A, Chang CC, et al. Association between plasma antibody responses and risk for cryptococcus-associated immune reconstitution inflammatory syndrome. J Infect Dis. 2019;219(3):420-428.

148. Scriven JE, Graham LM, Schutz C, et al. Aglucuronoxylomannan-associated immune signature, characterized by monocyte deactivation and an increased interleukin 10 level, is a predictor of death in cryptococcal meningitis. J Infect Dis. 2016;213(11):1725-1734.

149. Meya DB, Manabe YC, Boulware DR, Janoff EN. The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum. Curr Opin Infect Dis. 2016;29(1):10-22.

150. Corti D, Lanzavecchia A. Efficient methods to isolate human monoclonal antibodies from memory B cells and plasma cells. Antibodies Infect Dis. 2014;25(1):129-139.

How to cite this article: Okurut S, Boulware DR, Olobo J, Meya DB. Landmark clinical observations and immunopathogenesis pathways linked to HIV and Cryptococcus fatal central nervous system co-infection. Mycoses. 2020;63:840-853. https://doi.org/10.1111/myc.13122